The tumor microenvironment (TME) is essential for immune escape by tumor cells. It plays
essential roles in tumor development and metastasis. The clinical outcomes of tumors are …

Simple Summary In ovarian cancer, about 70% of patients experience relapse despite
primary cytoreductive surgery and platinum-based chemotherapy. The occurrence of …

While the presence of tumor-infiltrating lymphocytes (TILs) associates with improved survival
prognosis in ovarian cancer (OvCa) patients, TIL therapy benefit is limited. Here, we …

Introduction Targeted-immunotherapies such as antibody-drug conjugates (ADC), chimeric
antigen receptor (CAR) T cells or bispecific T-cell engagers (eg, BiTE®) all aim to improve …

Background Ovarian cancer (OC) is a highly aggressive gynecological malignancy
prevalent worldwide. Most OC cases are typically diagnosed at advanced stages, which has …

Simple Summary Ovarian cancer is the most lethal gynaecological malignancy, of which
serous carcinoma is the most common subtype. The lack of symptoms and sensitive …

Opinion statement Ovarian cancer (OC), especially high-grade serous cancer (HGSC), is a
highly heterogeneous malignancy with limited options for curative treatment and a high …

As the most lethal gynecologic oncological indication, carcinoma of the ovary has been
ranked as the 5th cause of cancer-related mortality in women, with a high percentage of the …

Platinum-resistant ovarian cancer is difficult to treat and has a poor prognosis. Patients with
platinum-resistant ovarian cancer have limited treatment options and often have a limited …

Background Fullerenes C60 shows great potential for drug transport. C60 generates large
amounts of singlet oxygen upon photoexcitation, which has a significant inhibitory effect on …